KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Invested Capital (2016 - 2025)

Charles River Laboratories International has reported Invested Capital over the past 17 years, most recently at $3.2 billion for Q4 2025.

  • For Q4 2025, Invested Capital fell 8.42% year-over-year to $3.2 billion; the TTM value through Dec 2025 reached $3.2 billion, down 8.42%, while the annual FY2025 figure was $3.2 billion, 8.42% down from the prior year.
  • Invested Capital for Q4 2025 was $3.2 billion at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $3.8 billion in Q3 2024 and troughed at $2.2 billion in Q1 2021.
  • A 5-year average of $3.1 billion and a median of $3.2 billion in 2025 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: grew 28.64% in 2021 and later decreased 12.23% in 2025.
  • Year by year, Invested Capital stood at $2.5 billion in 2021, then increased by 17.28% to $3.0 billion in 2022, then increased by 20.84% to $3.6 billion in 2023, then fell by 3.91% to $3.5 billion in 2024, then dropped by 8.42% to $3.2 billion in 2025.
  • Business Quant data shows Invested Capital for CRL at $3.2 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.4 billion in Q2 2025.